MAP Pharmaceuticals Acquired By Allergan

Mountain View-based MAP Pharmaceuticals, a publicly held developer of biopharmaceuticals aimed at treating migraines in adults, has been acquired by Allergan. The two said that Allergan will pay $25.00 per share for MAP, or approximately $958M, in the deal. Allergan was advised by Goldman, Sachs & Co. and Gibson, Dunn & Crutcher LLP in the deal; MAP Pharmaceuticals was advised by Centerview Partners LLC and Latham & Watkins LLP.